Beta-blockers and renal continuum


Cite item

Full Text

Abstract

Beta-blockers can be discussed as one of the approaches to limit chronic kidney disease progression, as well as to prevent cardiovascular complications in this patients. Therapeutic opportunities of beta-blockers should be explained by their effects on pathological sympathetic overactivation

References

  1. Salomonsson M, Brannstrom K, Arendshorst WJ. Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels:in vivo and in vitro studies. Am J Physiol 2000;278:F138-47.
  2. Moss NG, Colinders RE, Gottschalk CW. Neural control of renal function. In Windhager E.E. "Renal physiology" NY, Oxford University Press 1992.
  3. Арутюнов Г.П. Патофизиологические процессы в почках у больных хронической сердечной недостаточностью // Сердечная недостаточность. 2008. Т. 9. № 5. С. 234-50.
  4. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus,and hypertension in rats with chronic renal failure. Kidney International 1997;51:722-27.
  5. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-82.
  6. Ye S, Zhong H, Yanamadala V, et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15:717-24.
  7. Salplachta J, Bartosikova L, Necas J. Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys 2002;21:189-95.
  8. Amann K, Nichols C, Tornig J, et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-11.
  9. Jovanovic D, Jovovic D, Mihailovic-Stanojevic N, et al. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 2005;63:446-53.
  10. Amann K, Ritz E. Microvascular disease - the Cinderella of uraemic heart disease. Nephrol Dial Transplant 2000;15:1493-03.
  11. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: aprospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-44.
  12. Mann JF, Jakobs KH, Riedel J, et al. Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol 1986;250:H846-H852.
  13. Leineweber K, Heinroth-Hoffmann I, Ponicke K, et al. Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 2002;13:117-24.
  14. Rascher W, Schomig A, KreyeVA, et al. Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int 1982;21:20-27.
  15. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-18.
  16. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-28.
  17. Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-33.
  18. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-79.
  19. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardio-vascular events in patients with end-stage renal disease. Circulation 2002;105:1354-59.
  20. Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a10 year survey. Nephrol Dial Transplant 2004;19:1829-34.
  21. Zuanetti G, Maggioni AP, Keane W, et al. Nephrologists neglect administration of beta-blockers to dialysed diabetic patients. Nephrol Dial Transplant 1997;12:2497-500.
  22. Chobanian V, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
  23. Antman EM, Anbe DT, Armstrong PW, et al. A guideline for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association. Тask Force on Practice Guidelines. Circulation 2004;110:588-636.
  24. Cowburn PJ, Cleland JG, Coats AJ, et al. Risk stratification in chronic HF. Eur Heart J 1998;19:696-710.
  25. Parameshwar J, Keegan J, Sparrow J, et al. Predictors of prognosis in severe CHF. Am Heart J 1992;123:421-26.
  26. Ruilope LM, Van Veldhuisen DJ, Ritz E, et al. Renal function: the Cinderella of cardiovascular risk profile. JACC 2001;38:1782-87.
  27. Hampton JR, Van Veldhuisen DJ, Kleber FX, et al. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME-II) Investigators. Lancet 1997;349:971-77.
  28. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation and survival in patients with CHF. Circulation 2000;102:203-10.
  29. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe HF during treatment with enalapril - CONSENSUS trial. Am J Card 1992;70:479-87.
  30. Liethe M.E., Margorien R.D., Hermiller J.B. et al. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive HF. Circulation 1984;69:57-64.
  31. Elsner D. Changes in neurohormonal systems during the development of congestive HF: impact on cardiovascular and renal function. Eur Heart J 1995;(16, Suppl. N):52-58.
  32. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > 65 years of age with HF. Am J Card 2000;85:1110-13.
  33. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implication of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. JACC 2000;35:681-89.
  34. Smith GL, Vaccarino V, Kosiborod M, et al. Wosening renal function what is a clinically meaningful change in creatinine during hospitalization with HF. J Card Fail 2003;9:13-25.
  35. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive HF. J Card Fail 2002;8:136-41.
  36. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission and impact of worsening renal function among patients hospitalized with HF. JACC 2004;43:61-67.
  37. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3(4):469-79.
  38. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
  39. Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation 1998;98:I-378-I-379.
  40. Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation). Eur J Heart Fail 2004;6:467-75.
  41. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-90.
  42. Dyer AR, Persky V, et al. Heart rate as a prognostic factor for coronary heart disese and mortality: Findings in three Chicago epidemiological studies. Am J Epidemiol 1980;112(6):736-49.
  43. Beddhu S, Nigwekar SU, et al. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrology Dialysis Transplantation, doi: 10.1093/ndt/gfp057, published by Oxford University Press online on March 22, 2009.
  44. Sarafidis P, Bogojevic Z, Basta E, et al. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich) 2008;10:112-18.
  45. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258-65.
  46. Epstein M, Oster JR. Beta-blockers and renal function: a reappraisal. J Clin Hypertens 1985;1:85-99.
  47. Abbott KC, BakrisG. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol 1993;33:392-99.
  48. Zech P, Pozet N, Labeeuw M, et al. Acute renal effects of beta-blockers. Am J Nephrol 1986;6(Suppl. 2):15-19.
  49. Sugino G, Barg AP, O'Connor DT. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension. Am J Kidney Dis 1984;3:357-61.
  50. Dreslinski GR, Messerli FH, Dunn FG, et al. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. Circulation 1982;65:1365-68.
  51. Yasumoto R, Asakawa M, Kakinoki K, et al. Effect of metoprolol in patients with renal hypertension. Hinyokika Kiyo 1988;34:1669-73.
  52. van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha-and beta-adrenoceptor antagonists. Drugs 1993;45:509-17.
  53. Malini PL, Strocchi E, Negroni S, et al. Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol 1982;13:123S-126S.
  54. Wallin JD. Adrenoreceptors and renal function. J Clin Hypertens 1985;1:171-78.
  55. Keusch G, Weidmann P, Ziegler WH, et al. Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. Klin Wochenschr 1980;58:25-29.
  56. Dupont AG, Vander NP, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987;10(Suppl. 11):S130-S136.
  57. Tomita K, Makumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992;19(Suppl. 1):S97-S101.
  58. Coresh J, Wei GL, Mc Quillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: finding from the third national Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001;161:1207-16.
  59. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to know? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906.
  60. UKPD Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
  61. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ (ClinResEd) 1987;294:1443-47.
  62. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36 646-61.
  63. Tindall H, Urquhart S, Stickl M, et al. Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. Curr Med Res Opin 1991;12:516-20.
  64. Agarwal R. Supervise atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999;55:1528-35.
  65. Bakris G, Hart P, Ritz E. Beta-blockers in the management of chronic kidney disease. Kidney Int 2006;70:1905-13.
  66. Wright J, Bakis G, et al. от группы African American Study of Kidney Disease and Hypertension. JAMA 2002;288:2421-31.
  67. Kalaitzidis R, Bakris G. Should nephrologists use beta-blockers? A perspective Nephrology Dialysis Transplantation 2009;24(3):701-02.
  68. Mehrotra S, Ling KL, Bekele Y, et al. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus. Diabet Med 2001;18:109-15.
  69. Dupont AG. Carvedilol and the kidney. Clin Invest 1992;70(Suppl. 1):S127-S131.
  70. Kohno M, Takeda T, Ishii M, et al. Therapeutic benefits and safety of carvedilol in thetreatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan. Drugs 1988;36(Suppl. 6):129-35.
  71. Takeda T, Kohno M, Ishii M, et al. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. Eur J Clin Pharmacol 1990;38(Suppl. 2):S158-S163.
  72. Nowicki M, Szewczyk-Seifert G, Klimek D, et al. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 2002;57:352-58.
  73. Calo L, Giacon B, Davis PA, et al. Oxidative stress and TG Fbetain kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. ClinNephrol 2002;58:103-10.
  74. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25. <http://ndt.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=circulationaha&resid=113/9/1213>

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies